Aventis Will Re-Occupy 70,000 SF at Morris Corporate Center IV

The re-occupancy entails two full floors in Building Pod B of the two-building complex, which is owned by SJP Properties of Parsippany. The remaining 270,000 sf is still on the market for lease, with The Staubach Co.'s New Jersey offices in Murray Hill handling the assignment for Aventis. Managing principals Daniel J. Loughlin and Thomas J. Stanton, III are leading the effort.

"With this decision, we now have the opportunity to offer a number of leasing options for prospective tenants who require space from 35,000 sf up to full-building users," according to Loughlin, whose firm has a multi-tenant marketing program in place for the asset. "Aventis' occupancy will satisfy an immediate need for training and conference facilities, but it is a use that could be readily relocated, enabling a full-building user to sublease the facility."

"We want the corporate and brokerage communities to understand that our decision to re-occupy the building enables us to aggressively solicit all prospective requirements, regardless of size or term," adds Bob Cull, North American real estate manager for Aventis. Built three years ago, the asset sits on a 35-acre site near I-80, I-280, I-287 and Route 46.

Aventis Pharmaceuticals focuses its activities on such areas as cardiology, oncology, anti-infectives, arthritis, allergies and respiratory problems, diabetes and the central nervous system. Last year the company generated sales of $15.9 billion, spent $2.7 billion on R&D and employs 75,000 people in its core businesses around the world.